Literature DB >> 32651941

That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19.

Matthew R Davis1, Erin K McCreary2, Jason M Pogue3.   

Abstract

Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally benefit from remdesivir therapy, especially while drug supply is scarce. In this review, we analyze pertinent clinical remdesivir data for patients with COVID-19 from January 1, 2020, through May 31, 2020.

Entities:  

Keywords:  ACTT-1; Antiviral; COVID-19; Coronavirus disease 2019; Remdesivir; SARS-CoV-2

Year:  2020        PMID： 32651941     DOI： 10.1007/s40121-020-00318-1

Source DB:  PubMed          Journal:  Infect Dis Ther        ISSN： 2193-6382


  8 in total

Review 1.  COVID-19: breaking down a global health crisis.

Authors:  Saad I Mallah; Omar K Ghorab; Sabrina Al-Salmi; Omar S Abdellatif; Tharmegan Tharmaratnam; Mina Amin Iskandar; Jessica Atef Nassef Sefen; Pardeep Sidhu; Bassam Atallah; Rania El-Lababidi; Manaf Al-Qahtani
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-05-18       Impact factor: 3.944

2.  Effect of time and titer in convalescent plasma therapy for COVID-19.

Authors:  Paola de Candia; Francesco Prattichizzo; Silvia Garavelli; Rosalba La Grotta; Annunziata De Rosa; Agostina Pontarelli; Roberto Parrella; Antonio Ceriello; Giuseppe Matarese
Journal:  iScience       Date:  2021-07-22

Review 3.  Passive immunization and its rebirth in the era of the COVID-19 pandemic.

Authors:  Charles S Pavia; Gary P Wormser
Journal:  Int J Antimicrob Agents       Date:  2021-01-02       Impact factor: 5.283

4.  A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort.

Authors:  Tyler W Ackley; Dayna McManus; Jeffrey E Topal; Brian Cicali; Sunish Shah
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

5.  Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.

Authors:  Brian T Garibaldi; Kunbo Wang; Matthew L Robinson; Scott L Zeger; Karen Bandeen-Roche; Mei-Cheng Wang; G Caleb Alexander; Amita Gupta; Robert Bollinger; Yanxun Xu
Journal:  JAMA Netw Open       Date:  2021-03-01

Review 6.  Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?

Authors:  Esther Y Bae; James M Sanders; Meagan L Johns; Kevin Lin; Jessica K Ortwine; Wenjing Wei; Norman S Mang; James B Cutrell
Journal:  Curr Infect Dis Rep       Date:  2021-12-11       Impact factor: 3.725

7.  Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response.

Authors:  Maddalena Marconato; Irene A Abela; Anthony Hauser; Magdalena Schwarzmüller; Rheliana Katzensteiner; Dominique L Braun; Selina Epp; Annette Audigé; Jacqueline Weber; Peter Rusert; Eméry Schindler; Chloé Pasin; Emily West; Jürg Böni; Verena Kufner; Michael Huber; Maryam Zaheri; Stefan Schmutz; Beat M Frey; Roger D Kouyos; Huldrych F Günthard; Markus G Manz; Alexandra Trkola
Journal:  J Clin Invest       Date:  2022-06-15       Impact factor: 19.456

Review 8.  Convalescent Plasma Therapy for COVID-19: State of the Art.

Authors:  Daniele Focosi; Arthur O Anderson; Julian W Tang; Marco Tuccori
Journal:  Clin Microbiol Rev       Date:  2020-08-12       Impact factor: 26.132
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.